BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 5, 2007
View Archived Issues
AVEO Signs Potential $477M Schering-Plough Collaboration
Cancer drug company AVEO Pharmaceuticals Inc. is partnering a preclinical antibody program with Schering-Plough Corp. for worldwide development and commercialization in a deal that could be worth up to $477.5 million. (BioWorld Today)
Read More
Pfizer Taps pSivida Delivery: Up To $165M For Eye Drugs
Read More
Sangart Raises $50M In Series F For Blood Substitute Programs
Read More
Roche Ends 10-Year Court Fight By Acquiring BioVeris For $600M
Read More
Affimed Brings In $33.4M To Support Antibody Programs
Read More
Correction
Read More
Other News To Note
Read More
Clinic Roundup
Read More